Quest Diagnostics Plans 4-5% Revenue Growth Through 2025

At its March 19, 2025 Investor Day, Quest Diagnostics outlined its strategies for sustainable growth and long-term shareholder value, reaffirming its 2025 guidance. The company anticipates revenue growth at a 4-5% compound annual growth rate (CAGR) and adjusted earnings per share (EPS) growth at 7-9% CAGR beyond 2025. Key initiatives include expanding market access, enhancing diagnostics, and modernizing IT systems through its Project Nova initiative, which aims to improve productivity and customer experiences. Despite facing a $25 million revenue impact from adverse weather conditions in Q1 2025, Quest remains optimistic about growth in both physician and hospital channels. The company highlighted its focus on advanced diagnostics and strategic partnerships to drive further growth. Overall, Quest Diagnostics is positioning itself to meet evolving healthcare demands while maintaining a strong outlook for the future.